Avid Bioservices, Inc. (NASDAQ:CDMO – Get Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 15,080,000 shares, an increase of 31.0% from the May 31st total of 11,510,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 14.6 days.
Avid Bioservices Trading Down 0.3 %
CDMO traded down $0.02 during midday trading on Monday, reaching $7.12. 1,276,222 shares of the company’s stock traded hands, compared to its average volume of 1,192,050. Avid Bioservices has a 52 week low of $4.07 and a 52 week high of $14.28. The stock has a market capitalization of $451.98 million, a price-to-earnings ratio of -26.37 and a beta of 1.36. The firm has a fifty day moving average of $7.97 and a two-hundred day moving average of $7.21. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.46 and a quick ratio of 0.31.
Avid Bioservices (NASDAQ:CDMO – Get Free Report) last announced its earnings results on Wednesday, April 24th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.06). Avid Bioservices had a negative return on equity of 8.78% and a negative net margin of 13.10%. The firm had revenue of $33.82 million during the quarter, compared to the consensus estimate of $33.80 million. On average, equities analysts anticipate that Avid Bioservices will post -0.23 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Avid Bioservices
Insider Buying and Selling
In related news, CEO Nicholas Stewart Green sold 11,762 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $7.40, for a total transaction of $87,038.80. Following the completion of the transaction, the chief executive officer now directly owns 203,606 shares in the company, valued at $1,506,684.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 17,236 shares of company stock worth $127,546 over the last ninety days. 2.39% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. CWM LLC grew its stake in shares of Avid Bioservices by 3,125.0% in the 4th quarter. CWM LLC now owns 6,708 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 6,500 shares during the last quarter. Mather Group LLC. purchased a new stake in shares of Avid Bioservices in the 1st quarter worth approximately $46,000. Oxford Asset Management LLP purchased a new stake in shares of Avid Bioservices in the 4th quarter worth approximately $68,000. Evoke Wealth LLC purchased a new stake in shares of Avid Bioservices in the 4th quarter worth approximately $125,000. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Avid Bioservices in the 4th quarter worth approximately $132,000. Institutional investors own 97.16% of the company’s stock.
About Avid Bioservices
Avid Bioservices, Inc, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.
Read More
- Five stocks we like better than Avid Bioservices
- How to Invest in the FAANG Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Learn Technical Analysis Skills to Master the Stock Market
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Buy Cheap Stocks Step by Step
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.